Reviewed by MedNext Clinical Team
The global opioid crisis has fundamentally changed how clinicians approach pain management. In the United States alone, opioid-related overdose deaths have exceeded 80,000 per year [1]. In the United Kingdom and across Europe, a parallel rise in opioid-related harm — though less acute — has prompted significant concern. Yet undertreated pain remains a genuine clinical problem, and opioids retain an important role in acute pain, cancer pain, and carefully selected chronic pain scenarios. Safe opioid prescribing requires a structured risk-benefit framework applied at every prescribing decision.
Understanding the Opioid Risk Landscape
Acute Versus Chronic Use
The risk profile of opioids changes substantially with duration of use. Short-course opioids for acute pain — post-operative analgesia, renal colic, fractures — carry a comparatively low risk of dependence when prescribed for fewer than five days. The risk of developing opioid use disorder increases markedly with prescription duration: patients prescribed opioids for more than 30 days have a significantly higher rate of long-term use than those prescribed shorter courses [1].
Chronic opioid therapy for non-cancer pain remains one of the most contested areas in modern medicine. A landmark systematic review by Chou et al. found that evidence for the long-term effectiveness of opioids for chronic non-cancer pain is limited, while the evidence for harms — including dependence, cognitive impairment, endocrine effects, and overdose — is substantial [2].
Identifying High-Risk Patients
Several patient-level factors increase the risk of opioid-related harm and should inform the prescribing decision [1]:
- Prior history of substance use disorder — the strongest individual predictor of opioid misuse
- Psychiatric comorbidities — depression, PTSD, and anxiety disorders are associated with higher rates of opioid misuse and overdose
- Concurrent benzodiazepine or CNS depressant use — combination with opioids dramatically increases overdose risk
- Sleep-disordered breathing — opioid-induced respiratory depression is amplified in obstructive sleep apnoea
- Social isolation — reduces access to emergency intervention in overdose
- Renal or hepatic impairment — alters opioid metabolism and clearance, increasing drug accumulation [2]
Dose Equivalence and Safe Initiation
Opioid dose equivalence — the ability to convert between different opioid agents and routes of administration — is a foundational clinical skill and a common source of prescribing error [1]. Morphine milligram equivalents (MME) provide a standardised unit of comparison, with oral morphine as the reference agent.
Key equivalences to know:
- Oral codeine 240 mg ≈ oral morphine 24 mg (conversion ratio approximately 10:1)
- Oral tramadol 400 mg ≈ oral morphine 40 mg (conversion ratio approximately 10:1)
- Oral oxycodone 10 mg ≈ oral morphine 15 mg (conversion ratio approximately 1.5:1)
- Oral morphine to subcutaneous morphine: divide by 2
- Fentanyl patches require careful body weight and opioid tolerance assessment
When initiating opioid therapy, start at the lowest effective dose. The CDC Clinical Practice Guideline recommends that for opioid-naive patients, prescribers should start with immediate-release formulations and avoid extended-release or long-acting opioids for acute pain [1]. Extended-release formulations should be reserved for patients with established opioid tolerance and should never be used for as-needed dosing.
Monitoring During Opioid Therapy
Patients on ongoing opioid therapy require structured monitoring. Key parameters to review at each clinical encounter include [1,2]:
- Analgesia — is the opioid providing meaningful pain relief? If not, the risk-benefit calculation shifts unfavourably
- Function — is the patient's physical and social functioning maintained or improving?
- Aberrant behaviours — requests for early refills, lost prescriptions, multiple prescribers, use for indications other than pain
- Adverse effects — constipation, sedation, cognitive impairment, hormonal effects (hypogonadism with long-term use)
- Respiratory function — particularly in patients with sleep apnoea or on concurrent CNS depressants [2]
Deprescribing: A Clinical Imperative
When opioid therapy is no longer providing meaningful benefit, or when risks outweigh benefits, deprescribing is appropriate. Abrupt cessation in opioid-dependent patients causes a withdrawal syndrome that, while not life-threatening in healthy adults, is deeply distressing and a major driver of self-escalation and illicit drug use [1].
A structured tapering approach — typically reducing the total daily dose by 10% every two to four weeks — is better tolerated than rapid reduction. Patients should be warned about withdrawal symptoms including anxiety, diaphoresis, myalgia, and insomnia, and reassured that these are temporary. Adjunctive medications such as clonidine may assist with autonomic withdrawal symptoms during the taper.
MedNext Formulary provides dosing guidance, dose equivalence data, and renal/hepatic adjustment information for opioid agents within the MedNext Audited Proprietary Dataset, supporting safer prescribing and structured deprescribing at the point of care.
References
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
- Chou R, Turner JA, Devine EB, et al. The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-286.